MarketsandMarkets Biomarker and Companion Diagnostics Conference

WHAT TO EXPECT

Commercialization of CDx
Proteomics and Genomics based Biomarkers.
Biomarker Drug Discovery and Assay Development
Multiplex Companion Diagnostics and Regulatory Guidelines
Design of clinical trials in CDx
Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data
Clinical Applications of Biomarkers in Immuno-Oncology, Neurology, and Inflammatory Diseases

Hear from and meet with the key industry and academic innovators in biomarkers, translational medicine, clinical development, and diagnostics.
Discover the latest integration of biomarkers in early drug development through case studies by major pharma on multiple therapeutic areas, including immuno-oncology, neuroscience, cardiology, immunology respiratory rare diseases, and cell and gene therapies.
Gain novel insights into key biomarkers for detection, monitoring, and diagnosis, including innovative applications of digital markers.
Benefit from case studies on topical technology innovation within digital pathology, AI & imaging, flow cytometry, multiplexing, mass spectrometry and spatial biology tools.
Unparalleled networking opportunities. The two-day congress offers an interactive platform for high-level scientific and business discussions. Participate in formal or informal discussions during our networking breaks and pre-organised 1-2-1 meetings.

Researchers, scientists, clinicians, academicians and professionals from pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Pathology
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development
Personalized Medicine
Immunology Biomarkers

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
CLINICAL BIOMARKER DRUG DEVELOPMENT AND PRECISION MEDICINE
Aligning Innovation with Precision Medicine Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca	09:00 - 09:30
Gene expression signatures: key success factors Eike Staub, Head, Oncology Bioinformatics, Merck Healthcare, Germany	09:30 - 10:00
Transforming Oncology with Predicine’s Liquid Biopsy Solutions Shidong Jia, Founder, CEO, Predicine	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Solution Provider Presentation	11:15 - 11:45
Analysis of biomarkers in circulating fluids-emerging trend in liquid biopsy	11:45 - 12:15
Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs Allan Stensballe, Associate Professor, Aalborg University	12:15 - 12:45
Lunch and Poster Presentation \| One-to-One Networking Meeting	12:45 - 13:45
Why do 95% of oncology drugs fail in clinical development, and how can biomarkers help? Philip Beer, Chief Scientific Officer, Step Pharma	13:45 - 14:15
Use of omics technologies in biomarker discovery and profiling	14:15 - 14:45
Precision medicine in rare diseases – learnings and opportunities Thomas Hach, Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement, Novartis	14:45 - 15:15
Evening Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:15 - 15:45
Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data Katarzyna Wac, Full Professor, Computer Science, University of Geneva	15:45 - 16:15
When over 99% of published Biomarkers end up in the bin what can we do to reduce this waste and pick out the ones that could be rescued? Christopher Peters, Clinical Senior Lecturer, Imperial College London	16:15 - 16:45
Panel Discussion: Clinical biomarker development is critical to bring precision medicine from a scientific concept into clinical practice-Views? Louis Boon, CSO , JJP Biologics Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche Christopher Peters, Clinical Senior Lecturer, Imperial College London	16:45 - 17:15
Closing Remarks from the Chairperson	17:15 - 17:15
Drinks Reception & Networking	17:15 - 17:15
End of Day 1	17:15 - 17:15

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
CDX DEVELOPMENT, INTEGRATION AND COMMERCIALIZATION: CLINICAL APPLICATIONS OF CDX
Keynote Presentation Jürgen Scheuenpflug, Global Head Clinical Biomarkers & Companion Diagnostics, Merck Healthcare KGaA	09:00 - 09:30
Point-of-Care quantitative lateral flow diagnostic tests Aart van Amerongen, Senior scientist BioSensing & Diagnostics (BSD) , Wageningen UR	09:30 - 10:00
Next generation technologies in metabolic disease diagnosis and therapeutic effectiveness Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:30
Solution Provider Presentation	11:30 - 12:00
Regulatory considerations, approvals, reimbursement surrounding CDx	12:00 - 12:30
Challenges of measuring novel biomarkers using plate-based methods in large clinical studies Daniel Chapman, Post Doctoral Research Fellow, University of Oxford	12:30 - 13:00
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:00 - 14:00
Panel Discussion: Challenges and opportunities to integrate biomarker in clinical trial development-How to use the power of biomarker to accelerate clinical development?	14:00 - 14:30
Future directions in CDx-liquid biopsy, multi-marker panels and integration of CDx with precision medicine	14:30 - 15:00
Closing Remarks from the Chairperson	15:00 - 15:05
End of the conference	15:05 - 15:05